טוען...
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies
Human cytomegalovirus (HCMV) is an important pathogen in transplant patients and in congenital infection. Previously, we demonstrated that vaccination with a recombinant viral glycoprotein B (gB)/MF59 adjuvant formulation before solid organ transplant reduced viral load parameters post transplant. R...
שמור ב:
| הוצא לאור ב: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
National Academy of Sciences
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004462/ https://ncbi.nlm.nih.gov/pubmed/29686064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1800224115 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|